---
type: entity
entity_type: company
name: Mark Cuban Cost Plus Drug Company
founded: 2022
headquarters: Dallas, TX
founders: Mark Cuban, Alex Oshmyansky
status: active
website: costplusdrugs.com
domain: health
tags: [pharmacy, drug-pricing, PBM-alternative, generics, biosimilars]
---

# Mark Cuban Cost Plus Drug Company

## Overview

Cost Plus Drug Company is a direct-to-consumer pharmacy founded in 2022 by Mark Cuban and Alex Oshmyansky. The company operates on a transparent pricing model: acquisition cost + 15% markup + $3 pharmacy fee + $5 shipping, offering over 2,300 medications (primarily generics).

## Business Model

**Pricing Structure:**
- Acquisition cost + 15% fixed fee
- No insurance intermediation for direct-to-consumer sales
- Transparent pricing published online

**Product Portfolio:**
- 2,300+ medications (mostly generics)
- Expanding into biosimilar portfolio
- Pursuing US manufacturing expansion with generic drug fee waivers

**Distribution Strategy:**
- Partnership with Humana CenterWell Pharmacy for employer prescription solutions (2025)
- Combines Cost Plus pass-through pricing with CenterWell distribution infrastructure
- Dependent on incumbent partnerships rather than independent distribution

## Market Position

**Competitive Context:**
- Big Three PBMs (CVS Caremark, OptumRx, Express Scripts) control ~80% of US prescription claims
- Cost Plus operates as challenger model coexisting with incumbents
- Growing market share but partnering with incumbents (Humana) rather than displacing PBMs

**Political Role:**
- Mark Cuban testified at congressional hearings on PBM practices
- Supported FTC investigations into PBM business practices
- Functions as political/narrative pressure vehicle even with small market share

## Limitations

- Primarily generic drugs — does not address branded/biologic drugs where margins are highest
- No owned distribution infrastructure — dependent on partnerships
- No clinical services layer — drug pricing tool, not care delivery model
- Has not achieved meaningful market share in specialty drugs where margin extraction is concentrated

## Timeline

- **2022** — Company founded by Mark Cuban and Alex Oshmyansky
- **2025-11** — Partnership announced with Humana CenterWell Pharmacy for employer prescription solutions
- **2026** — Expanding biosimilar portfolio and pursuing US manufacturing expansion